An article in the November issue of IEEE Computer Magazine (Sloot et al., From Molecule to Man: Decision Support in Individualized E-Health) turned me on to Virolab. This is a European Union-funded prototype "virtual laboratory" that the project page describes as follows:
...a virtual laboratory will be developed enabling easy access to distributed resources as well as sharing, processing and analysing virological, immunological, clinical and experimental data. As a prototype for this virtual laboratory for infectious diseases, the problem of HIV drug resistance will be used. The virtual laboratory will integrate the biomedical information from viruses (proteins and mutations), patients (e.g. viral load) and literature (drug resistance experiments) resulting in a rule-based distributed decision support system for drug ranking. In addition ViroLab will include advanced tools for (bio) statistical analysis, visualization, modelling and simulation, enabling prediction of the temporal virological and immunological response of viruses with complex mutation patterns for drug therapy.
The system seems to me to be very well thought through. It is targeted initially at a very important medical challenge, but this single focus is an artifact of its being a proof-of-concept project; the underlying technology is generically applicable to all manner of challenges in medical research and clinical care.
Continue reading "The future of health IT, today: Virolab" »